Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Cancer Res. 2019 Oct 31;80(1):102–115. doi: 10.1158/0008-5472.CAN-19-1957

Figure 5.

Figure 5.

VCP inhibitors increase PM NIS expression and function. A, TPC-1 (NIS+) cells treated with VCP inhibitors (ebastine, clotrimazole, and astemizole). B and C, Western blot (B) and RAI uptake (C) analyses of VCP expression following VCP-siRNA depletion and treatment with 0.5 μmol/L ebastine (top), 0.25 μmol/L clotrimazole (middle), 0.25 μmol/L astemizole (bottom) in TPC-1 (NIS+) cells. D and E, Cell-surface biotinylation assay analysis of NIS protein levels at the PM relative to Na+/K+ ATPase in the TPC-1 (NIS+) cell line after treatment with 0.5 μmol/L ebastine, 0.25 μmol/L clotrimazole, or 0.25 μmol/L astemizole. F, Western blot analysis of VCP expression in TPC-1 (NIS+) cells following treatment with 0.5 μmol/L ebastine, 0.25 μmol/L clotrimazole, or 0.25 μmol/L astemizole. G, Schematic indicating protocol for obtaining mouse thyrocytes. H and I, RAI uptake (H) and Western blot analysis (I) in mouse thyrocytes treated with 0.5 μmol/L ebastine (n = 8) or 0.25 μmol/L clotrimazole (n = 8). J, RAI uptake in human thyrocytes treated as described with ebastine or clotrimazole at varying of doses of VCP inhibitors due to previous evidence of variability in VCP inhibitor sensitivity (50). *, P < 0.05; **, P < 0.01.